

=====

Sequence Listing could not be accepted due to errors.

See attached Validation Report.

If you need help call the Patent Electronic Business Center at (866)  
217-9197 (toll free).

Reviewer: markspencer

Timestamp: [year=2010; month=1; day=27; hr=10; min=15; sec=52; ms=475; ]

=====

\*\*\*\*\*

Reviewer Comments:

1.

nbsp; Empty lines found between the amino acid numbering and  
the proteins SEQID ( 2 )

E321 No. of Bases conflict, this line has no nucleotides  
SEQID (2) POS (464)

E355 Empty lines found between the amino acid numbering and  
the proteins SEQID ( 2 )

E321 No. of Bases conflict, this line has no nucleotides  
SEQID (2) POS (464)

W112 Upper case found in data; Found at position(0) SeqId(2)

W112 Upper case found in data; Found at position(1) SeqId(2)

W112 Upper case found in data; Found at position(2) SeqId(2)

W112 Upper case found in data; Found at position(3) SeqId(2)

E259 Found undefined lettercode; POS (5) SEQID(2)

E259 Found undefined lettercode; POS (6) SEQID(2)

E259 Found undefined lettercode; POS (7) SEQID(2)

E259 Found undefined lettercode; POS (8) SEQID(2)

E259 Found undefined lettercode; POS (9) SEQID(2)

E259 Found undefined lettercode; POS (10) SEQID(2)

E259 Found undefined lettercode; POS (11) SEQID(2)

E259 Found undefined lettercode; POS (12) SEQID(2)

E259 Found undefined lettercode; POS (13) SEQID(2)

<210> 2

<211> 475

<212> PRT

<213> Homo sapiens

<220>

<223> Peptide sequence of double mutant His310-H435Lys.

<400> 2

Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly	Lys
465					470					475

4

1

WASH\_6680526.1

The Sequence Listing file must end at the bottom of the last SEQ ID #. There can be no extra information following the last SEQ ID # in the file. Please remove extra information, "4", "1", and "WASH\_6680526.1" found at the end of the file, after SEQ ID # 2.

2.

<110> LABORATOIRE FRANÇAIS DU FRACTIONNEMENT ET DES  
BIOTECHNOLOGIES

BOUREL, Dominique

GLACET, Arnaud

JORIEUX, Sylvie

STURA, Enrico

DUCANCEL, Frédéric

TEILLAUD, Jean-Luc

<120> USE OF METALLIC CATIONS TO IMPROVE FUNCTIONAL ACTIVITY  
OF ANTIBODIES

<130> D 21 711 NT

<140> 10576440

<141> 2010-01-08

<150> PCT/FR2004/002687

<151> 2004-10-20

<150> FR 03 12228

<151> 2003-10-20

<160> 2

<170> PatentIn version 3.3

The sequence listing must be in ASCII text format. This file contains non-ASCII text characters, see numeric identifier <110> the accent marks in the name "Frédéric". Please make all changes necessary to convert this file to ASCII text only.

\*\*\*\*\*

Application No: 10576440 Version No: 1.0

Input Set:

Output Set:

Started: 2010-01-08 14:18:39.238  
 Finished: 2010-01-08 14:18:43.864  
 Elapsed: 0 hr(s) 0 min(s) 4 sec(s) 626 ms  
 Total Warnings: 4  
 Total Errors: 13  
 No. of SeqIDs Defined: 2  
 Actual SeqID Count: 2

Error code	Error Description
E 355	Empty lines found between the amino acid numbering and the
E 321	No. of Bases conflict, this line has no nucleotides SEQID (2)
E 355	Empty lines found between the amino acid numbering and the
E 321	No. of Bases conflict, this line has no nucleotides SEQID (2)
W 112	Upper case found in data; Found at position(0) SeqId(2)
W 112	Upper case found in data; Found at position(1) SeqId(2)
W 112	Upper case found in data; Found at position(2) SeqId(2)
W 112	Upper case found in data; Found at position(3) SeqId(2)
E 259	Found undefined lettercode; POS (5) SEQID(2)
E 259	Found undefined lettercode; POS (6) SEQID(2)
E 259	Found undefined lettercode; POS (7) SEQID(2)
E 259	Found undefined lettercode; POS (8) SEQID(2)
E 259	Found undefined lettercode; POS (9) SEQID(2)
E 259	Found undefined lettercode; POS (10) SEQID(2)
E 259	Found undefined lettercode; POS (11) SEQID(2)
E 259	Found undefined lettercode; POS (12) SEQID(2)
E 259	Found undefined lettercode; POS (13) SEQID(2)

<210> 1  
<211> 1428  
<212> DNA  
<213> Homo sapiens

<220>  
<223> cDNA sequence of double mutant His310-435Lys

<400> 1  
atggagtttg ggctgagctg ggttttcctc gttgctcttt taagaggtgt ccagtgtcag 60  
gtgcagctgg tggagtctgg gggaggcgtg gtccagcctg ggaggtcct gagactctcc 120  
tgtacagcct ctggattcac cttcaaaaac tatgetatgc attgggtccg ccaggctcca 180  
gccaaagggc tggagtgggt ggcaactata tcatatgatg gaaggaatat acaatatgca 240  
gactccgtga agggccgatg caccttctcc agagacaatt ctcaggacac cctgtatctg 300  
caactgaaca gcctcagacc ggaggacacg gctgtgtatt actgtgcgag acccgtaaga 360  
agccgatggc tgcaattagg tcttgaagat gcttttcata tctggggcca ggggacaatg 420  
gtcacctgtc cttcagctc caccaagggc ccatcggtct tccccctggc accctctccc 480  
aagagcacct ctgggggcac agcggccctg ggctgcctgg tcaaggacta cttccccgaa 540  
ccggtgacgg tgctctggaa ctcaggcgcc ctgaccagcg gcgtgcacac cttccccggt 600  
gtcctacagt ctcaggact ctactccctc agcagcgtgg tgaccgtgcc ctcagcagc 660  
ttgggcaccc agacctacat ctgcaacgtg aatcacacgc ccagcaacac caaggtggac 720  
aagaaagttg agcccaaata ttgtgacaaa actcacacat gccacccgtg cccagcacct 780  
gaactcctgg ggggaccgtc agtcttctc tccccccaa aaccaagga caccctcatg 840  
atctcccga cccctgaggt cacatgcgtg gtggtggacg tgagccacga agaccctgag 900  
gtcaagtcca actggtacgt ggacggcgtg gaggtgcata atgccaagac aaagccgcgg 960  
gaggagcagt acaacagcac gtaccgtgtg gtcagcgtcc tcaccgtcct gaagcaggac 1020  
tggtctaatg gcaaggagta caagtgcag gtctccaaca aagccctccc agccccatc 1080  
gagaaaacca tctccaaagc caaagggcag ccccgagaac cacaggtgta caccctgcc 1140  
ccatcccggt atgagctgac caagaaccag gtcagcctga cctgcctggt caaaggettc 1200  
tatccacgag acatgcgcgt ggagtgggag agcaatgggc agccggagaa caactacaag 1260  
accacgctc ccgtgtgga ctcgacggc tccttcttcc tctacagcaa gctcacctg 1320  
gacaagagca ggtggcagca ggggaacgtc ttctcatgct ccgtgatgca tgaggctctg 1380  
cacaacaagt acacgcagaa gagcctctcc ctgtctccgg gtaaatag 1428

<210> 2  
<211> 475  
<212> PRT  
<213> Homo sapiens

<220>  
<223> Peptide sequence of double mutant His310-H435Lys.

<400> 2

Met Glu Phe Gly Leu Ser Trp Val Phe Leu Val Ala Leu Leu Arg Gly  
1 5 10 15

Val Gln Cys Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln  
20 25 30

Pro Gly Arg Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe  
35 40 45

Lys Asn Tyr Ala Met His Trp Val Arg Gln Ala Pro Ala Lys Gly Leu  
50 55 60

Glu Trp Val Ala Thr Ile Ser Tyr Asp Gly Arg Asn Ile Gln Tyr Ala  
65 70 75 80

Asp Ser Val Lys Gly Arg Cys Thr Phe Ser Arg Asp Asn Ser Gln Asp  
85 90 95

Thr Leu Tyr Leu Gln Leu Asn Ser Leu Arg Pro Glu Asp Thr Ala Val  
100 105 110

Tyr Tyr Cys Ala Arg Pro Val Arg Ser Arg Trp Leu Gln Leu Gly Leu  
115 120 125

Glu Asp Ala Phe His Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser  
130 135 140

Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser  
145 150 155 160

Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp  
165 170 175

Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr  
180 185 190

Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr  
195 200 205

Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln  
210 215 220

Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp  
225 230 235 240

Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro  
245 250 255

Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro  
260 265 270

Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr  
275 280 285

Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn  
290 295 300

Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg  
305 310 315 320

Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val  
325 330 335

Leu Lys Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser  
340 345 350

Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys  
355 360 365

Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp  
370 375 380

Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe  
385 390 395 400

Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu

405

410

415

Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe  
420 425 430

Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly  
435 440 445

Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn Lys Tyr  
450 455 460

Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys  
465 470 475

4

1

WASH\_6680526.1